What is the difference in the efficacy of Mobotinib (Mobosetinib) and Suvotinib?

Mobocertinib) and suvotinib (Furmonertinib), as lung cancer targeted drugs that have attracted much attention in recent years, are mainly used to treat patients with Furmonertinib span>EGFRmutated non-small cell lung cancer (NSCLC) patients, especially for rare mutations such as EGFR Targeted therapy of Exon20insertion mutations provides new options. Although the two have partial overlap in indications, there are still significant differences in drug mechanisms, applicable populations, efficacy performance, and side effects.

From a drug mechanism perspective, Mobotinib is an oral tyrosine kinase inhibitor (TKI) specifically developed for EGFR Exon20 insertion mutations. It was developed by Takeda Pharmaceuticals of the United States and is the world's first targeted drug approved by the FDA for the treatment of EGFR Exon20ins mutation-positive metastatic non-small cell lung cancer. It can selectively inhibit abnormal EGFR activity caused by Exon20 insertion mutations, and provide new treatment options for patients who are resistant to traditional EGFR targeted drugs (such as erlotinib and osimertinib). Suvotinib is a new generation of EGFR-TKI independently developed in China. Although it was initially mainly used for EGFR Treatment of patients with 19deletions and 21 mutations, but subsequent studies also found that it has certain activity against some Exon20 insertion mutations, and shows broad-spectrum targeting capabilities in multiple mutation subtypes.

In terms of clinical efficacy, the efficacy of mobotinib mainly comes from the data of the EXCLAIM study. This study shows that forEGFR In patients with Exon20ins mutations, the overall response rate (ORR) of mobotinib is approximately 28%, and the median progression-free survival (PFS) is 7.3 months, and the median overall survival (OS) can reach about 24 months. In contrast, although suvotinib is not specifically designed to target Exon20ins mutations, some studies and real-world data also show that it still responds in some patients with Exon20 mutations, and ORR can reach 25% or so.PFScan also be maintained for more than 6 months. It is particularly worth mentioning that suvotinib has significant efficacy in patients with traditional EGFR sensitive mutations, and ORR can be achieved70%above, PFScan exceed 12 months, showing its broad clinical adaptability.

In terms of adverse reactions, common side effects of Mobotinib include diarrhea, rash, nausea, stomatitis and prolongation of the QT interval. In particular, the incidence of diarrhea is high. About 80% of patients will experience varying degrees of gastrointestinal discomfort. Therefore, it is necessary to focus on clinically monitoring changes in electrolytes and electrocardiograms. Suvotinib is relatively well tolerated. Common side effects include rash, elevated transaminases, and mild diarrhea, which can generally be controlled through dose adjustment and symptomatic treatment. Its safety performance in long-term treatment is considered relatively stable, and it is suitable for some elderly or weak patients.

Generally speaking, both mobotinib and suvotinib have their own advantages. Mobotinib is the first clear approved treatmentEGFR Drugs targeting Exon20 insertion mutations are the preferred treatment for patients with this mutation type; Suvotinib, as a new domestic drug, is not only suitable for common EGFR mutation types, but also shows certain activity against some rare mutations such as Exon20ins, with both efficacy and cost-effectiveness. Therefore, in clinical selection, doctors usually flexibly select appropriate drug regimens based on factors such as the patient's mutation type, economic status, previous medication history, and individual tolerance to achieve the best therapeutic effect.

With the continuous advancement of precision medicine, these two drugs are expected to be more explored in the fields of combination therapy and sequential medication in the future, bringing broader treatment prospects to patients with non-small cell lung cancer. For patients, understanding the characteristics and differences of different targeted drugs can help them participate in treatment decisions more scientifically and achieve personalized treatment goals.

References：https://en.wikipedia.org/wiki/Mobocertinib